Press Releases May 28, 2026 08:30 AM

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Feature Management at 2026 Jefferies Global Healthcare Conference

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals announces that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference, highlighting the company's ongoing drug development efforts across multiple therapeutic areas including neuropathic pain, hypertrophic cardiomyopathy, obesity, and other cardiometabolic conditions.

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lexicon Pharmaceuticals will present at a major healthcare investment conference, providing exposure to investors and analysts.
  • The company is advancing a diverse pipeline with candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.
  • The event will be available live and via replay on the company website, enhancing accessibility for stakeholders.

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals    
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Media Inquiries: 
Dave Belian 
Lexicon Pharmaceuticals, Inc. 
lexinvest@lexpharma.com  
  
For Investor Inquiries: 
Lisa DeFrancesco 
Lexicon Pharmaceuticals, Inc. 
lexinvest@lexpharma.com 


Risks

  • Clinical and regulatory risks inherent in drug development could impact future progress and approvals.
  • Market competition in pharmaceuticals and biotechnologies may affect Lexicon's commercial success.
  • Investor sentiment may be tempered if the presentation lacks new or substantial data updates.

More from Press Releases

Cipher Digital Inc. Announces Proposed Offering of $810.0 Million of Senior Secured Notes Jun 8, 2026 Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal Jun 8, 2026 Global-e to Participate in Morgan Stanley US Financials Conference Jun 8, 2026 Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses Jun 8, 2026 Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives Jun 8, 2026